Thus, the TP53/MIR34A “double hit” characterizes a very aggressive subgroup of DLBCL, which may be treatable with epigenetic therapy prior to or in combination with conventional immunochemotherapy. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.